Nationwide Lifespan Trends in Cardiac Implantable Electronic Device Strategies in Japan: Age‐Dependent Changes in Transvenous and Epicardial Systems Authors: Aya Miyazaki, Gaku Izumi, Shuhei Fujita, Tsugutoshi Suzuki, Hiroshi Suzuki, Jun Yoshimoto, Keiko Toyohara, Yasunobu Hayabuchi, Masahiko Takagi Published: 2026 ABSTRACT ABSTRACTBackgroundNationwide epidemiological studies of cardiac implantable electronic devices (CIEDs) encompassing multiple device types and strategies remain limited in Japan, particularly regarding epicardial lead use and pediatric populations.MethodsWe performed the first nationwide analysis of CIED implantation trends using the National Database of Health Insurance Claims, including transvenous (TV)/epicardial (Epi) systems for pacemakers, implantable cardioverter‐defibrillators (ICDs), cardiac resynchronization therapy (CRT), and CRT‐defibrillators (CRTDs), as well as leadless pacemakers, subcutaneous ICDs (S‐ICDs), and epicardial lead use. Epicardial lead and pediatric characteristics were supplemented using industry data.ResultsIn fiscal year 2023, implantation rates per 100 000 population were 29.69 for TV‐pacemakers, 7.06 for leadless pacemakers, 2.42 for TV‐ICDs, 0.889 for S‐ICDs, 1.20 for TV‐CRT, and 1.69 for TV‐CRTDs. Rates for epicardial systems were lower, at 0.173 for Epi‐pacemakers, 0–0.007 for Epi‐ICDs, 0.024 for Epi‐CRT, and 0.027 for Epi‐CRTDs, while epicardial lead use was 0.545. S‐ICD use increased across age groups, whereas TV‐ICD implantation declined (all p < 0.001). Implantation of TV and leadless pacemakers, TV‐CRT, and TV‐CRTDs increased over time (all p < 0.001). Epicardial lead use showed a bimodal age distribution, peaking in pediatric and elderly populations, and declined in older adults while remaining stable in children and adults aged 20–49 years (p < 0.001). Pediatric CIED volumes were low, with several ICD, CRT, and CRTD procedures annually.ConclusionsCIED strategies in Japan demonstrate age‐dependent variation. Epicardial systems remain indispensable in pediatric and congenital heart disease care, whereas alternative technologies are increasingly adopted in older adult populations, reflecting evolving lifespan‐related device strategies. Introduction In Japan, several large‐scale databases provide insights into clinical practice related to cardiac implantable electronic devices (CIEDs), but each has important limitations. The New Japan Cardiac Device Treatment Registry (New JCDTR), established by the Japanese Heart Rhythm Society, collects detailed procedural data on implantable cardioverter‐defibrillators (ICDs), cardiac resynchronization therapy (CRT), and cardiac resynchronization therapy defibrillators (CRTDs) [1]. However, it does not include pacemaker procedures and is based on voluntary participation, thereby limiting its ability to capture nationwide trends comprehensively. Similarly, the Japanese Registry of All Cardiac and Vascular Diseases (JROAD) provides institutional and hospitalization data from participating cardiovascular centers. However, it is limited by its survey‐based design and incomplete national coverage [2]. In contrast, the National Database of Health Insurance Claims (NDB) offers near‐complete nationwide coverage of procedural data across all device types, albeit with limited clinical detail [3]. The Japan Arrhythmia Device Industry Association (JADIA) [4], an industry association representing companies involved in the manufacture and distribution of CIEDs, publishes data on device supply volumes; however, data on lead characteristics and age‐specific distributions are not publicly available. Despite these data sources, comprehensive nationwide data on CIEDs in pediatric patients and adults with congenital heart disease (CHD) remain limited in Japan. A recent nationwide questionnaire survey conducted across 119 institutions in 2024 reported 2411 cases of abdominal CIED implantation, most of which involved epicardial lead systems [5]. However, this survey was limited to institutions caring for pediatric and CHD patients and did not provide nationwide coverage. A comprehensive understanding of CIED use in patients with epicardial leads and broader pediatric populations remains lacking. Such knowledge is essential for characterizing current practice patterns and guiding future clinical strategies. In this study, we aimed to define the overall landscape and temporal trends of CIED implantation in Japan, with a particular focus on epicardial leads and pediatric populations. Using the NDB [3], we analyzed implantation procedures for pacemakers, ICDs, CRT, and CRTDs, including both transvenous and epicardial systems, as well as leadless pacemakers and subcutaneous implantable cardioverter‐defibrillators (S‐ICDs), and separately evaluated epicardial lead use. To complement the nationwide procedural data obtained from the NDB, we further examined detailed characteristics of epicardial lead use and pediatric CIED procedures using additional data obtained through collaboration with JADIA [4]. Methods Data Collections The National Database of Health Insurance Claims (NDB) [3] The National Database of Health Insurance Claims (NDB) [3] The National Database of Health Insurance Claims (NDB) [3] The NDB is an open‐access database provided by the Ministry of Health, Labour and Welfare (MHLW), which has contained data on health insurance claims and specific health checkup and guidance programs since 2008. The first NDB Open Data Japan was released in 2016, presenting data from fiscal year (FY) 2014. FYs were defined according to the Japanese fiscal year (April–March). The NDB provides procedural and medical device use data tabulated by age, sex, and prefecture, but does not include detailed patient background information such as underlying diseases. The FY2023 dataset included public reimbursement claims, which were not included in the data from FY2014 to FY2022. The following data were extracted by sex and age group: The number of claims for pacemaker, ICD, CRT, and CRTD implantation procedures using transvenous and epicardial leads, as well as leadless pacemaker and S‐ICD implantation proceduresThe number of claims for unipolar and bipolar epicardial leads. The number of claims for pacemaker, ICD, CRT, and CRTD implantation procedures using transvenous and epicardial leads, as well as leadless pacemaker and S‐ICD implantation procedures The number of claims for pacemaker, ICD, CRT, and CRTD implantation procedures using transvenous and epicardial leads, as well as leadless pacemaker and S‐ICD implantation procedures The number of claims for unipolar and bipolar epicardial leads. The number of claims for unipolar and bipolar epicardial leads. Reimbursement coverage for procedures involving CRT, ICD, and CRTD using epicardial leads began in FY2020; therefore, these data have been available since FY2020. Before FY2020, claims did not distinguish between transvenous and epicardial leads. The S‐ICD and leadless pacemaker became available in Japan in 2016 and 2017, respectively, and have been covered by insurance since their introduction. Data on unipolar and bipolar epicardial leads have been available in the NDB since FY2016. For the analysis of devices with epicardial leads and S‐ICDs, only inpatient data were used, whereas outpatient data were also included for other CIEDs. However, only transvenous and leadless pacemaker implantation procedures were captured in the outpatient setting. To comply with the minimum cell size policy of the NDB and to prevent potential re‐identification, any cell with a count of fewer than 10 was suppressed and represented by a hyphen “‐”, in accordance with the specifications of the NDB Open Data. In addition, when only one category contained a value of fewer than 10, the smallest value greater than or equal to 10 was also masked and indicated by a hyphen. In the data for FY2022 and FY2023, a value of “0” was used to indicate an actual count of zero, except for the FY2023 data on ICDs with epicardial leads. However, in the data prior to FY2021 and in the FY2023 data on ICDs with epicardial leads, “0” was not used. Total and age‐specific procedure rates per 100 000 population for CIED implantation and epicardial lead use were calculated to evaluate national trends across the following age groups: 0–19, 20–49, 50–64, 65–74, 75–84, and ≥ 85 years. Age groups were defined a priori based on clinically relevant life‐stage categories. Total and age‐specific population data were obtained from the Statistics Bureau of Japan using population estimates as of October 1 of each year [6]. When the exact numbers of procedures in the total population or age‐specific groups were unavailable due to masking of small cell sizes, the smallest plausible values were used to calculate total and age‐specific procedure rates. IIThe database by Japan Arrhythmia Device Industry Association (JADIA) [4] IIThe database by Japan Arrhythmia Device Industry Association (JADIA) [4] The database by Japan Arrhythmia Device Industry Association (JADIA) [4] The data for FY 2021–2023 were obtained from JADIA through two companies (Medtronic Japan Co. Ltd. and Abbott Medical Japan LLC) supplying epicardial leads in Japan. During this period, Medtronic supplied both suture (unipolar and bipolar) and sutureless (unipolar) epicardial leads, while Abbott supplied sutureless bipolar epicardial leads [7]. The available information included only proportions of the total number of cases. The exact numbers were not disclosed because the sales volumes of each company could be inferred from these data, given that only two companies supply epicardial leads in Japan. For pediatric CIED implantations, devices from manufacturers other than Medtronic and Abbott are also used; however, data from these companies were not available. The provided data included the following items: The proportion of implantation sites among the total number of epicardial leads.The proportion of the number of epicardial leads used per patient among all patients with epicardial leads.The proportion of the types of CIEDs connected to epicardial leads among the total number of patients with epicardial leads.The proportion of new CIED implantations among the total number of procedures in the pediatric age group, including those using both transvenous and epicardial leads. The proportion of implantation sites among the total number of epicardial leads. The proportion of implantation sites among the total number of epicardial leads. The proportion of the number of epicardial leads used per patient among all patients with epicardial leads. The proportion of the number of epicardial leads used per patient among all patients with epicardial leads. The proportion of the types of CIEDs connected to epicardial leads among the total number of patients with epicardial leads. The proportion of the types of CIEDs connected to epicardial leads among the total number of patients with epicardial leads. The proportion of new CIED implantations among the total number of procedures in the pediatric age group, including those using both transvenous and epicardial leads. The proportion of new CIED implantations among the total number of procedures in the pediatric age group, including those using both transvenous and epicardial leads. Statistical Analysis Comparisons of implantation rates across age groups and temporal trends in CIED implantation rates and epicardial lead use were evaluated using Poisson regression models, with age group included as a categorical variable (reference: 65–74 years) and FY treated as a continuous variable. The logarithm of the population was included as an offset. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were calculated. Interaction terms between FY and age group were included to assess whether temporal trends differed across age groups. Temporal trends in the proportion of bipolar versus unipolar epicardial leads were assessed using weighted logistic regression analysis. An odds ratio (OR) with a 95% CI was calculated to quantify the annual change in bipolar lead use. Statistical analyses were carried out using JMP version 19 software (SAS Institute, Cary, NC, USA). A two‐sided p‐value of < 0.05 was considered statistically significant. Results Number of Claims for Pacemaker Implantation Procedures With Transvenous and Epicardial Leads, and Leadless Pacemaker Implantation The data for procedures with transvenous leads, those with epicardial leads, and leadless pacemakers are presented in Figure 1A–C and Tables S1–S3, respectively. Total procedure rates per 100 000 population in FY2023 were 29.69 for transvenous leads, 0.173 for epicardial leads, and 7.06 for leadless pacemakers (Table 1 and Figure 2). Number of claims for CIED implantation by age group (years) for pacemakers with transvenous leads (A), pacemakers with epicardial leads (B), and leadless pacemakers (C), ICDs with transvenous leads (D), S‐ICDs (E), CRT with transvenous leads (F) and CRTDs with transvenous leads (G). CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; CRTD, cardiac resynchronization therapy defibrillator; FY, fiscal year; ICD, implantable cardioverter‐defibrillator; S‐ICD, subcutaneous ICD. TABLE 1Total procedure rates per 100 000 population for epicardial lead use and CIED implantations [3, 6].Fiscal yearPopulation (×1000)Pacemaker implantationICD implantationCRT implantationCRTD implantationEpicardial lead useWith transvenous leadsWith epicardial leadsLeadlessWith transvenous leadsWith epicardial leadsS‐ICDWith transvenous leadsWith epicardial leadsWith transvenous leadsWith epicardial leads2014127 08327.7790.2462.5600.4391.3242015127 09528.5350.2272.5570.4921.3432016126 93329.0240.2192.4590.4660.5441.4330.7412017126 70630.4360.2290.1422.2650.6750.5861.5210.7622018126 44329.5060.1862.2552.3200.6920.7141.4770.7092019126 16730.4130.1792.2662.2160.7760.8431.5490.6572020126 14629.8870.1632.3062.0670–0.0070.6900.8290.0291.4680.0250.6182021125 50230.1730.1513.1272.1280–0.0070.6470.8240.0241.4310.0210.5272022124 94728.4160.1534.8542.1740.0120.6370.9140.0241.5160.0170.5402023124 35229.6880.1737.0612.4210–0.0070.8891.1970.0241.6860.0270.545Abbreviations: CIED, cardiac implantable electronic device; CRT, cardiac resynchronization Therapy; CRTD, cardiac resynchronization therapy defibrillator; ICD, implantable Cardioverter‐defibrillator; S‐ICD, subcutaneous ICD. Total procedure rates per 100 000 population for epicardial lead use and CIED implantations [3, 6]. Abbreviations: CIED, cardiac implantable electronic device; CRT, cardiac resynchronization Therapy; CRTD, cardiac resynchronization therapy defibrillator; ICD, implantable Cardioverter‐defibrillator; S‐ICD, subcutaneous ICD. Trends in procedure rates per 100 000 population in Japan for transvenous CIEDs, leadless PMs and S‐ICDs (A), and for epicardial CIEDs (B). CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; CRTD, cardiac resynchronization therapy defibrillator; Epi, epicardial; FY, fiscal year; ICD, implantable cardioverter‐defibrillator; PM, pacemaker; S‐ICD, subcutaneous ICD; TV, transvenous. For pacemaker implantation with transvenous leads, comparisons across age groups showed that, compared with patients aged 65–74 years, implantation rates were significantly higher in patients aged 75–84 years (IRR 3.37, 95% CI 3.34–3.40), and ≥ 85 years (IRR 5.08, 95% CI 5.04–5.13) (all p < 0.001) (Figure 3A). The overall implantation rate increased slightly over time (IRR per year 1.004, 95% CI 1.003–1.006, p < 0.001). Interaction analyses showed that temporal trends were largely similar across most age groups; however, compared with the reference group (65–74 years), a significant decline was observed in patients aged 50–64 years (IRR 0.98, 95% CI 0.97–0.99, p < 0.001). When examined within each age group, implantation rates significantly decreased in older age groups, including patients aged 50–64, 65–74, 75–84, and ≥ 85 years, with annual decreases of approximately 3.0%, 1.7%, 1.4% and 1.2%, respectively (all p < 0.001). In contrast, no significant temporal trends were observed in the 0–19 (p = 0.81)‐year age group or 20–49–year age group (p = 0.50). Trends in age‐specific procedure rates per 100 000 population in Japan for pacemakers with transvenous leads (A), pacemakers with epicardial leads (B), leadless pacemakers (C), ICDs with transvenous leads (D), S‐ICDs (E), CRT with transvenous leads (F), and CRTDs with transvenous leads (G). CRT, cardiac resynchronization therapy; CRTD, cardiac resynchronization therapy defibrillator; FY, fiscal year; ICD, implantable cardioverter‐defibrillator; S‐ICD, subcutaneous ICD. For pacemaker implantation with epicardial leads, a bimodal age distribution was observed, with peaks in patients younger than 14 years and those older than 65 years (Figure 1B). Comparisons across age groups showed that, compared with patients aged 65–74 years, implantation rates were significantly higher in patients aged 0–19 years (IRR 2.81, 95% CI 2.36–3.34), 75–84 years (IRR 2.93, 95% CI 2.43–3.52), and ≥ 85 years (IRR 3.41, 95% CI 2.78–4.18) (all p < 0.001). In contrast, significantly lower rates were observed in patients aged 20–49 years (IRR 0.29, 95% CI 0.18–0.47) and 50–64 years (IRR 0.25, 95% CI 0.13–0.48) (all p < 0.001) (Figure 3B). The overall implantation rate significantly decreased over time (IRR per year 0.95, 95% CI 0.93–0.96, p < 0.001). The interaction terms between FY and age group were not statistically significant. When examined within each age group, implantation rates significantly decreased in older age groups, including those aged 65–74, 75–84, and ≥ 85 years, with annual decreases of approximately 21.2%, 20.5%, and 10.9%, respectively (all p < 0.001). In contrast, no significant temporal trends were observed in younger age groups. For leadless pacemaker implantation, comparisons across age groups showed that, compared with patients aged 65–74 years, implantation rates were significantly lower in patients aged 0–19 years (IRR 0.002, 95% CI 0.001–0.009, p < 0.001), 20–49 years (IRR 0.009, 95% CI 0.006–0.013, p < 0.001), and 50–64 years (IRR 0.11, 95% CI 0.10–0.13, p < 0.001), whereas significantly higher implantation rates were observed in patients aged 75–84 years (IRR 5.36, 95% CI 5.14–5.60, p < 0.001) and ≥ 85 years (IRR 14.91, 95% CI 14.29–15.55, p < 0.001) (Figure 3C). The overall implantation rate increased over time (IRR per year 1.39, 95% CI 1.38–1.40, p < 0.001). Interaction analyses showed no significant year‐by‐age group interactions. When examined within each age group, implantation rates significantly increased in patients aged 20–49, 50–64, 65–74, 75–84, and ≥ 85 years, with annual increases of approximately 114%, 58%, 29%, 32%, and 39%, respectively (all p < 0.001). In contrast, no significant temporal trend was observed in patients aged 0–19 years. Number of Claims for ICD Implantation Procedures With Transvenous and Epicardial Leads, as Well as S‐ICD Implantation The data for procedures with transvenous leads, those with epicardial leads and S‐ICDs are presented in Figure 1D,E, Tables S4 and 2. Total procedure rates per 100 000 population in FY2023 were 2.42 for transvenous leads, 0–0.007 for epicardial leads, and 0.889 for S‐ICD, respectively (Table 1 and Figure 2). TABLE 2Number of claims for implantable cardiac defibrillator (ICD), cardiac resynchronization therapy (CRT), and cardiac resynchronization therapy defibrillator (CRTD) implantation procedures with epicardial leads by sex and age group [3].Fiscal yearNumber of claimsSexAge group (years)0–45–910–1415–1920–2425–2930–3435–3940–4445–4950–5455–5960–6465–6970–7475–7980–8485–89≧90ICD implantation procedures with epicardial leads (Medical procedure code: 150415510)2023 b —Male———————————————————Female———————————————————Male + Female c UnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkown2022 a 15Male—0—000—0—00—————000Female0—00000—00000000—0—Male + Female c ≧ 1≧ 1≧ 1000≧ 1≧ 1≧ 100≧ 1≧ 1≧ 1≧ 1≧ 1≧ 10≧ 12021 b —Male———————————————————Female———————————————————Male + Female c UnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkown2020 b —Male———————————————————Female———————————————————Male + Female c UnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownUnkownCRT implantation procedures with epicardial leads (Medical procedure code: 150415110)2023 a 35Male—00————000————————0Female———000—00—000————00Male + Female c ≧ 2≧ 1≧ 1≧ 1≧ 1≧ 1≧ 200≧ 1≧ 1≧ 1≧ 1≧ 2≧ 2≧ 2≧ 2≧ 102022 a 30Male————0000—000—0————0Female—00——0—0000000——000Male + Female c ≧ 2≧ 1≧ 1≧ 2≧ 10≧ 10≧ 1000≧ 10≧ 2≧ 2≧ 1≧ 102021 b 30Male———————————————————Female———————————————————Male + Female c UnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknown2020 b 37Male———————————————————Female———————————————————Male + Female c UnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownCRTD implantation procedures with epicardial leads (Medical procedure code: 150415810)2023 a 34Male00000000—0—0—————00Female0000000000—0————000Male + Female c 00000000≧ 10≧ 20≧ 2≧ 2≧ 2≧ 2≧ 1002022 a 21Male0000000—0——00—————0Female00000000—00000———00Male + Female c 0000000≧ 1≧ 1≧ 1≧ 100≧ 1≧ 2≧ 2≧ 2≧ 102021 b 26Male———————————————————Female———————————————————Male + Female c UnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknown2020 b 31Male———————————————————Female———————————————————Male + Female c UnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownUnknownAbbreviations: CRT, cardiac resynchronization Therapy; CRTD, cardiac resynchronization therapy defibrillator; ICD, implantable Cardioverter‐defibrillator. a “—”: Indicates values from 1 to 9 and also masks the smallest value greater than or equal to 10 when there is only one category with a value less than 10. b “—”: Indicates values less than 10, and also masks the smallest value greater than or equal to 10 when there is only one category with a value less than 10. c The data were derived from the data of the National Database of Health Insurance Claims (NDB). Number of claims for implantable cardiac defibrillator (ICD), cardiac resynchronization therapy (CRT), and cardiac resynchronization therapy defibrillator (CRTD) implantation procedures with epicardial leads by sex and age group [3]. Abbreviations: CRT, cardiac resynchronization Therapy; CRTD, cardiac resynchronization therapy defibrillator; ICD, implantable Cardioverter‐defibrillator. “—”: Indicates values from 1 to 9 and also masks the smallest value greater than or equal to 10 when there is only one category with a value less than 10. “—”: Indicates values less than 10, and also masks the smallest value greater than or equal to 10 when there is only one category with a value less than 10. The data were derived from the data of the National Database of Health Insurance Claims (NDB). For ICD implantation with transvenous leads, implantation rates in patients aged 75–84 years did not differ significantly from those in patients aged 65–74 years (Figure 3D). The overall implantation rate significantly decreased over time (IRR per year 0.98, 95% CI 0.98–0.99, p < 0.001). Significant interactions between FY and age group were observed, indicating that temporal trends differed by age group. Compared with patients aged 65–74 years, the implantation rates increased in older patients, including those aged 50–64 years (IRR 1.06, 95% CI 1.04–1.08), 75–84 years (IRR 1.09, 95% CI 1.07–1.11), and ≥ 85 years (IRR 1.08, 95% CI 1.05–1.11) (all p < 0.001). In contrast, decreases were observed in younger patients aged 0–19 years (IRR 0.76, 95% CI 0.69–0.83, p < 0.001) and 20–49 years (IRR 0.97, 95% CI 0.95–0.99, p = 0.012). When examined within each age group, implantation rates significantly decreased in younger and middle‐aged patients, including those aged 0–19, 20–49, and 50–64 years, with annual decreases of approximately 29.9%, 10.6%, and 2.4%, respectively (all p < 0.001). In contrast, no significant temporal trends were observed in the ≥ 65‐year age groups. For ICD implantation using epicardial leads, the total number of procedures was fewer than 10 in FY2020, FY2021, and FY2023, whereas it was 15 in FY2022. Owing to the small sample size, graphical presentation and statistical analysis were not feasible; therefore, the detailed data are presented in Table 2. For S‐ICD implantation, comparisons across age groups showed that, compared with patients aged 65–74 years, implantation rates of S‐ICD were significantly higher in those aged 50–64 years (IRR 1.27, 95% CI 1.18–1.36, p < 0.001) (Figure 3E). The overall implantation rate increased significantly over time (IRR per year 1.05, 95% CI 1.03–1.06, p < 0.001). Interaction terms between FY and age group were not statistically significant. When examined within each age group, implantation rates increased significantly in patients aged 20–49, 50–64, 65–74, and 75–84 years, with annual increases of approximately 3.9% (p < 0.001), 7.4% (p < 0.001), 4.7% (p < 0.001), and 6.6% (p = 0.0029), respectively. In contrast, no significant temporal trends were observed in the 0–19 (p = 0.068) or ≥ 85‐year age groups (p = 0.58). Number of Claims for CRT Implantation Procedures With Transvenous and Epicardial Leads The data for procedures with transvenous leads and those with epicardial leads are presented in Figure 1F, Tables S4 and 2. Total procedure rates per 100 000 population in FY2023 were 1.20 for transvenous leads and 0.024 for epicardial leads, respectively (Table 1 and Figure 2). For CRT with transvenous leads, comparisons across age groups showed that, compared with patients aged 65–74 years, implantation rates were significantly higher in patients aged 75–84 years (IRR 3.18, 95% CI 3.01–3.35), and ≥ 85 years (IRR 2.63, 95% CI 2.47–2.80) (all p < 0.001) (Figure 3F). The overall implantation rate increased significantly over time (IRR per year 1.11, 95% CI 1.10–1.11, p < 0.001). Interaction terms between FY and age group were not statistically significant. When examined within each age group, implantation rates increased significantly in patients aged 50–64, 65–74, 75–84, and ≥ 85 years, with annual increases of approximately 11.7%, 7.0%, 9.1%, and 13.2%, respectively (all p < 0.001). For CRT with epicardial leads, the annual number of implantations ranged from 30 to 37 during FY2020–2023, and no significant temporal trend was observed in the implantation rate (Table 2 and Figure 2B). Number of Claims for CRTD Implantation Procedures With Transvenous and Epicardial Leads The data for procedures with transvenous leads and those with epicardial leads are presented in Figure 1G, Tables S4 and 2. Total procedure rates per 100 000 population in FY2023 were 1.69 for transvenous leads and 0.027 for epicardial leads, respectively (Table 2 and Figure 2B). For CRTD with transvenous leads, comparisons across age groups showed that, compared with patients aged 65–74 years, implantation rates were significantly higher in patients aged 75–84 years (IRR 1.18, 95% CI 1.14–1.22, p < 0.001) (Figure 3G). The overall implantation rate increased significantly over time (IRR per year 1.02, 95% CI 1.01–1.02, p < 0.001). Interaction terms between FY and age group were not statistically significant. When examined within each age group, implantation rates increased significantly in patients aged 65–74, 75–84, and ≥ 85 years, with annual increases of approximately 1.1% (p = 0.011), 2.0% (p < 0.001), and 7.9% (p < 0.001), respectively. For CRTD with epicardial leads, the annual number of implantations ranged from 21 to 34 during FY2020–2023, and no significant temporal trend was observed in the implantation rate (Table 2 and Figure 2B). Number of Claims for Epicardial Leads The data for Unipolar and Bipolar epicardial leads are presented in Figure 4 and Table S5. Total procedure rate per 100 000 population in FY2023 was 0.545 for epicardial lead use (Table 1 and Figure 4C). Trends in claims for epicardial lead use in Japan during fiscal years (FY) 2016–2023 (3). (A) Total number of implantations. (B) Number of implantations by age group (years). (C) Trends in age‐specific implantation rates per 100 000 population. Bipolar leads were more frequently used than unipolar leads (83% to 91%), and the proportion of bipolar leads increased significantly over time (OR per year 1.09, 95% CI 1.06–1.13, p < 0.001) (Figure 4A). A bimodal age distribution was observed, with peaks in pediatric and elderly patients (Figure 4B). Comparisons across age groups showed that, compared with patients aged 65–74 years, the use of epicardial leads was significantly higher in those aged 0–19 years (IRR 1.45, 95% CI 1.34–1.57) and 75–84 years (IRR 2.08, 95% CI 1.92–2.26) (all p < 0.001). In contrast, significantly lower use was observed in patients aged 20–49 years (IRR 0.26, 95% CI 0.23–0.29), 50–64 years (IRR 0.24, 95% CI 0.21–0.27), and ≥ 85 years (IRR 0.58, 95% CI 0.50–0.68) (all p < 0.001) (Figure 4C). The overall rate of epicardial lead use decreased significantly over time (IRR per year 0.94, 95% CI 0.93–0.95, p < 0.001), corresponding to an annual reduction of approximately 5.6% (Figure 5C). Interaction analyses showed that the temporal decline differed across age groups. Compared with the reference group (65–74 years), the decrease was more pronounced in patients aged 75–84 years (IRR 0.94, 95% CI 0.92–0.97), whereas the decline was attenuated or reversed in younger age groups, including those aged 0–19 years (IRR 1.08, 95% CI 1.05–1.10) and 20–49 years (IRR 1.09, 95% CI 1.05–1.12) (all p < 0.001). When examined within each age group, implantation rates decreased markedly in patients aged 65–74, 75–84, and ≥ 85 years, with annual decreases of approximately 14.6%, 11.7%, and 10.4%, respectively (all p < 0.001), whereas they remained largely unchanged in younger age groups. Data from the Japan Arrhythmia Device Industry Association (JADIA) [4] during fiscal years (FY) 2021 to 2023. (A) The proportion of implantation sites of epicardial leads among the total number of epicardial leads. (B) The proportion of the number of epicardial leads used per patient among all patients with epicardial leads. (C) The proportion of CIED types connected to epicardial leads among the total number of patients with epicardial leads. (D–G) show the proportion of the pediatric patients by age group (years) among the total number of new CIED implantations: PM (D), ICD (E), CRT (F), and CRTD (G). The data in (D–G) include all CIEDs with both transvenous and epicardial leads. “Total” represents data for patients aged 0–19 years. Blue and orange represent data from Medtronic Japan Co. Ltd. and Abbott Medical Japan LLC, respectively. CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; CRTD, cardiac resynchronization therapy defibrillator; FY, fiscal year; ICD, implantable cardioverter‐defibrillator; PM, pacemaker. The Data Analysis by Japan Arrhythmia Device Industry Association (JADIA) [4] The majority of epicardial leads were implanted in the ventricle in both companies throughout the study period (Figure 5A and Table S6). In Medtronic, ventricular implantation accounted for approximately 55%–59%, while atrial implantation accounted for 40%–44%. In Abbott, ventricular implantation was markedly dominant (93%–96%), with very low atrial use (4%–7%). Most patients received a single epicardial lead (Figure 5B and Table S6). In Medtronic, a single lead was used in 47%–55%, two leads in 41%–47%, and ≥ 3 leads in 4%–6%. In Abbott, a single lead was predominantly used in 85%–94%, with very few patients receiving multiple leads. Among patients with epicardial leads, pacemakers were the most common devices in both companies (60%–70%) (Figure 5C, Supplementary Table 6). A substantial proportion of leads were categorized as “None” (19%–30%), suggesting unused leads. ICD use was extremely rare. CRT and CRTD accounted for a small but consistent proportion (5%–8% and 1%–3%, respectively). From FY2021 to FY2023, the proportion of new CIED implantations in the pediatric population (0–19 years) remained low across all device types (Figure 5D–G and Table S7). The proportions of pacemaker, ICD, CRT, and CRTD implantations during FY2021–2023 ranged from 0.38%–0.59%, 0.16%–1.02%, 0.63%–2.03%, and 0.00%–0.24%, respectively. Across age groups, higher proportions of pacemaker implantation were observed in younger children (0–4 years), whereas ICD implantation tended to increase in older age groups (15–19 years). Discussion To our knowledge, comprehensive population‐based comparisons across multiple device types and lead strategies using nationwide data have been lacking, although previous epidemiological studies have reported overall CIED implantation volumes [8, 9]. In this nationwide analysis, implantation rates per 100 000 population for transvenous, leadless, and subcutaneous systems in FY2023 were 29.69 for pacemakers, 7.06 for leadless pacemakers, 2.42 for ICDs, 0.889 for S‐ICDs, 1.20 for CRT, and 1.69 for CRTDs. In contrast, rates for epicardial systems were substantially lower: 0.173 for pacemakers, 0–0.007 for ICDs, 0.024 for CRT, and 0.027 for CRTDs per 100 000 population. The overall rate of epicardial lead use was 0.545 per 100 000 population. Transvenous CIEDs, Leadless Pacemakers and S‐ICDs Peak implantation age group differed across transvenous, leadless, and subcutaneous systems: patients aged ≥ 85 years for pacemakers and leadless pacemakers, those aged 65–74 and 75–84 years for ICDs, those aged 50–64 years for S‐ICDs, and those aged 75–84 years for CRT and CRTD devices. These differences likely reflect variations in underlying disease substrates, clinical indications, and risk–benefit considerations across device types, resulting in age‐dependent differences in device selection. Distinct temporal patterns were observed across device types. Implantation rates increased for transvenous and leadless pacemakers, CRT, CRTD, and S‐ICD, whereas transvenous ICD implantation declined (Figure 2A). The divergence between transvenous ICD and S‐ICD trends represents one of the most clinically meaningful findings of this study. The decrease in transvenous ICD use, coupled with the rapid adoption of S‐ICD, indicates a substantial shift in device selection. A similar trend has been reported in analyses of the JROAD‐DPC database [10]. This transition was observed across multiple age groups, consistent with a strategy to minimize lead‐related complications over long‐term follow‐up. The increase in transvenous pacemaker implantation likely reflects population aging and the growing prevalence of conduction system disease [11]. However, the modest overall increase, combined with declining trends in older age strata, suggests that this growth may be reaching a plateau, potentially due to the rapidly increasing use of leadless pacemakers, improvements in medical therapy, and more selective indications [12]. Notably, the increase in leadless pacemaker implantation was particularly pronounced in elderly patients, especially those aged ≥ 85 years. Consistent with this, CRT and CRTD implantation rates increased significantly, particularly among older patients. These findings align with those reported in the Japan Cardiac Device Treatment Registry (JCDTR) and likely reflect both the increasing burden of heart failure and expanding indications for device therapy [13, 14]. The absence of significant interaction between age and temporal trends suggests that this growth is occurring relatively uniformly across age groups, although absolute rates remain highest in the elderly. Epicardial Leads and Epicardial CIED Implantation A key finding of this study is the distinct bimodal age distribution of epicardial lead use, with peaks in pediatric and older populations, underscoring the fundamentally different clinical roles of epicardial pacing across the lifespan. Overall epicardial lead use declined significantly over time, a trend largely driven by reductions in older populations, while rates remained relatively stable in pediatric patients and younger age groups. Pacemaker implantation with epicardial leads exhibited a similar age distribution and temporal pattern. These patterns likely reflect age‐specific clinical indications rather than variations in practice patterns. In pediatric patients and adults with CHD, epicardial leads remain indispensable due to small body size and limited venous access, resulting in sustained procedural demand over time [7, 15]. In contrast, among general adults, emerging alternatives such as leadless pacing have progressively reduced reliance on epicardial approaches [12]. In addition, the decline in epicardial lead implantation in elderly patients may reflect broader shifts in cardiovascular care. The reduced frequency of open surgical procedures, particularly for valvular heart disease, due to the widespread implementation of transcatheter therapies (e.g., transcatheter aortic valve implantation and transcatheter edge‐to‐edge repair), likely contributes to fewer opportunities for concomitant epicardial lead placement [16]. Importantly, despite the overall decline in use, the proportion of bipolar epicardial leads increased significantly over time. This shift likely reflects evolving device selection toward leads with superior electrical performance and durability. Bipolar epicardial leads are associated with lower pacing thresholds and improved long‐term stability [17], supporting their preferential use when epicardial implantation is required. Another notable observation is that approximately 30% of epicardial leads were implanted without immediate device connection, likely reflecting prophylactic lead placement during cardiac surgery in patients with CHD to anticipate future pacing needs [18]. These findings underscore the continued importance of epicardial leads in congenital and surgical contexts, despite their declining role in routine adult practice. As the adult CHD population grows, the demand for epicardial lead implantation may increase, particularly among younger and middle‐aged adults, given that nearly 30% of adult patients with CHD requiring CIED implantation have epicardial leads [19]. Furthermore, differences in epicardial lead utilization between the two companies—particularly the marked predominance of ventricular implantation and the lower frequency of multi‐lead implantation in Abbott systems—may reflect device‐specific characteristics. Abbott manufactures only sutureless (screw‐in) epicardial leads, which are generally less suitable for atrial placement. Pediatric Patients (0–19 Years) Interpretation of pediatric data from the NDB requires caution because small cell sizes (< 10 cases) are masked. Based on external data sources, including JADIA, the annual number of ICD, CRT, and CRTD implantations in pediatric patients is extremely low—typically ranging from only a few to several dozen cases per year, despite a pediatric population of approximately 20.4, 20.0, and 19.7 million in FY2021, FY2022, and FY2023, respectively. Pacemaker implantation accounted for the majority of pediatric CIED procedures. Despite these limitations, several important patterns emerged. Epicardial lead use and pacemaker implantation with epicardial leads remained stable in patients aged 0–19 years, underscoring its indispensable role in pediatric practice. This likely reflects the unique anatomical and clinical considerations in this population, for which epicardial systems often remain the preferred or only feasible option [15]. Notably, S‐ICD implantation was observed from as early as the 5–9‐year age group and was more frequently performed in adolescents aged ≥ 15 years. Although a statistically significant temporal increase was not observed in the pediatric population (p = 0.068), this distribution may reflect an evolving preference for S‐ICD systems among younger patients. This trend is clinically plausible given the advantages of S‐ICD in avoiding long‐term transvenous lead–related complications, which are of particular concern in patients with long life expectancy [20, 21]. Collectively, these findings highlight a clear divergence in device strategy in pediatric populations: continued reliance on epicardial systems for pacing, alongside increasing adoption of S‐ICD for defibrillation therapy. Limitations Several limitations should be acknowledged. First, this study was based on administrative claims data, and detailed clinical information, such as underlying diagnoses, disease severity, and procedural indications, was not available. In addition, small cell sizes (< 10 cases) were masked in accordance with NDB policy, and in some FYs, values may appear as zero or may not be reported. For statistical analyses, the smallest plausible values were imputed when necessary, which may have introduced a degree of uncertainty into the estimates. Second, coding changes over time may have influenced the observed trends, although efforts were made to harmonize procedure codes across study periods. Third, analyses of rare procedures, such as ICD implantation with epicardial leads, were limited by very small sample sizes, precluding robust statistical evaluation. Fourth, data obtained from external sources such as JADIA were available only in the form of proportions rather than absolute counts, which limited the ability to perform formal statistical analyses using these datasets. Finally, because the available data from JADIA represented only a proportion of the total number of implantations and did not include devices from all manufacturers, the findings regarding the characteristics of epicardial lead use and pediatric CIED procedures may not be fully generalizable. Conclusion In this nationwide study, transvenous CIED implantation showed device‐specific trends, indicating evolving, age‐dependent treatment strategies. In contrast, epicardial lead use showed a bimodal age distribution, underscoring its essential role in children and younger adults, likely reflecting CHD populations. Despite very low implantation volumes in pediatric patients, device strategies differed from those in the general adult population, with continued reliance on epicardial systems for pacing and increasing use of S‐ICD. These findings highlight the age‐dependent evolution of CIED implantation strategies in Japan, characterized by the sustained importance of epicardial approaches in pediatric and CHD care and a broader transition toward alternative systems in older adult populations, with important implications for the growing adult CHD population. Funding The authors have nothing to report. Disclosure Permission to reproduce material from other sources: Use of the National Database of Health Insurance Claims (NDB) is publicly authorized for clinical research and publication. Data from the Japan Arrhythmia Device Industry Association (JADIA) were used with permission for this publication. Ethics Statement This study was exempt from institutional review board approval because it used publicly available, non‐identifiable data, in accordance with applicable ethical guidelines. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Number of claims for pacemaker (PM) implantation procedures with transvenous leads (Medical procedure code: 150140210) by sex and age group (3). Table S2: Number of claims for pacemaker (PM) implantation procedures with epicardial leads (Medical procedure code: 150140110) by sex and age group (3). Table S3: Number of claims for leadless pacemaker (PM) implantation procedures (Medical procedure code: 150140110) by sex and age group (3). Table S4: Number of claims for implantable cardiac defibrillator (ICD), cardiac resynchronization therapy (CRT), and cardiac resynchronization therapy defibrillator (CRTD) implantation procedures with transvenous leads, and for subcutaneous implantable cardiac defibrillator (S‐ICD) implantation procedures, by sex and age group (3). Table S5: Number of claims for epicardial leads; Unipolar (Designated Medical Equipment Code: 736970000) and Bipolar (Designated medical Equipment Code: 736980000) by sex and age group (3). Table S6: The proportion of implantation sites of epicardial leads, the number of epicardial leads used per patient, and the types of CIEDs connected to epicardial leads (4). Table S7: The proportion of the new CIED implantations among the total number of procedures in pediatric age group, including those using both epicardial and transvenous lead (4).